Scholarships

The Hemophilia Alliance, The Alliance Pharmacy, and the Hemophilia Alliance Foundation are pleased to support the 2026-2027 Joe Pugliese Educational Award. This award is a scholarship provided annually to individuals diagnosed with an inherited bleeding or inherited thrombotic disorder who are active patients in a federally funded Hemophilia Treatment Center, in support of post-secondary educational pursuits. The 2026-2027 education award will provide each of four recipients with $12,500 for tuition and/or any qualified educational expense to be used within one academic year of award receipt. 

It is a shared goal of the Hemophilia Alliance and the Hemophilia Alliance Foundation that this scholarship program continues for many years to help support individuals with inherited bleeding or inherited thrombotic disorders throughout their education.

The EveryLife Foundation for Rare Diseases has established the #RAREis Scholarship Fund to help adults with rare diseases in a variety of educational pursuits, regardless of treatment status. Thanks to the support of Amgen, one-time awards of $5,000 each will be granted up to 88 recipients for the Fall 2025 semester.

The program is administered by Scholarship America®, the nation’s largest designer and manager of scholarships and other education support programs for corporations, foundations, associations, and individuals. Eligibility for individual programs is determined at the sole discretion of the sponsor, and eligible applications are reviewed by Scholarship America’s evaluation team. 

Applicants to the #RAREis Scholarship Fund must be:

• U.S. residents who have been diagnosed* by a physician as having any form of rare disease regardless of treatment status. Applicants will be asked to provide a Diagnosis Verification Form provided by a physician verifying diagnosis.
• Currently enrolled or planning to enroll full-time or part-time** in undergraduate or graduate study at an accredited two- or four-year college, university or vocational-technical/trade school for the Fall 2024 semester.
• 17 years old or older (no upper age limit, veterans and non-traditional students are encouraged.)

*Undiagnosed applicants may apply with completed Diagnosis Verification Form by a physician.
**There is no minimum amount of credit hours to be part-time (example, one class is considered part time).

This program offers scholarship opportunities to students living with a neuromuscular condition, primary immunodeficiency disease, or a bleeding disorder. The InfuCare Rx Scholarship Program helps people with chronic and complex medical conditions pursue higher education annually. 

Eligibility Requirements

Learn more about available scholarships by visiting InfuCare Rx® Scholarship Program homepage.

At Medexus Pharma, the goal is to help people with hemophilia B by providing high-quality, specialized therapies, connecting with people to learn about their needs, and developing empowering programs that enrich peoples’ lives. This program just for people with hemophilia B helps deliver a brighter future. 

Eligibility

• Be diagnosed with hemophilia B.
• Be a US citizen or legal US resident.
• Be entering or attending an accredited secondary education institution in the United States. Students who are pursuing or resuming a degree later in adulthood may apply even if there was a gap in their academic career.

This scholarship was formed to provide awareness of chronic disorders to the public and to stimulate, foster, and encourage interest, awareness, and activism at the state and national level with reference to the fight against chronic disorders.

Eligibility

• Applicants must be diagnosed with a bleeding disorder or other chronic disorder.
• Applicants MUST be Graduating from High School in the year of the Scholarship Award.
• Applicants must have applied to, been accepted at, an accredited college or university.

Visit the Lawrence Madeiros Scholarship contact page (www.thelmsf.org/contact) to submit further questions about award amounts, eligibility, and the application. 

This scholarship program is funded by Optum Infusion Pharmacy and administered by the Bleeding Disorders Foundation of North Carolina. Applicants are not required to be—nor is any preference given to—residents of North Carolina. 

Eligibility:

• Intended for persons affected by a bleeding disorder*, including anyone who has been diagnosed with a bleeding disorder; or is a caregiver of a child or adult affected by a bleeding disorder; or has a sibling or parent in the same household affected by a bleeding disorder.
• The applicant must be seeking education from an accredited college, university, or certified training program based in the United States.

*For the purpose of this scholarship application, the term “bleeding disorder” is limited to clotting factor deficiency disorders, specifically: hemophilia A (factor VIII), B (factor IX), and C (factor XI), von Willebrand Disease, factor V/parahemophilia**, factor VII, factor X, and factor XIII deficiencies. (**Factor V Leiden is a clotting disorder and is not eligible). Exceptions for bleeding disorders that result from other rare diseases may be considered by the scholarship committee on a case-by-case basis.

Note: Applicants to this program who have been diagnosed with hemophilia A will automatically be considered for the George D. McCoy/Bleeding Disorders Foundation of North Carolina Scholarship. There is no need to submit separate applications.

These scholarships are administered by the Bleeding Disorders Foundation of North Carolina. Applicants are not required to be—nor is any preference given to—residents of North Carolina. 

Eligibility

1. Optum® Infusion Pharmacy Scholarship
   1. Multiple awards of $500 to $3000
   2. Eligibility: Applicant may be any person affected by a bleeding disorder, including a family member of someone diagnosed with a bleeding disorder (see candidate criteria in the section below)
   3. Funded by Optum Infusion Pharmacy
2. George D. McCoy Education Scholarship
   1. $1000 award
   2. Eligibility: Applicant must be diagnosed with mild, moderate, or severe Hemophilia A
   3. Funded by Bleeding Disorders Foundation of North Carolina

Any applicant diagnosed with hemophilia A is automatically considered for both scholarships.

Brandywine Valley Hemophilia Foundation (BVHF) is pleased to make available a $2000.00 scholarship to an individual impacted by hemophilia or other significant bleeding disorder. Once chosen as the recipient, the scholarship will be renewed each year for four years as long as the individual remains in good academic standing. A check will be made payable to the educational institution and mailed to the recipient each year following verification of continuing education and an adequate academic record. 

Eligibility

• Any individual within our service area who is diagnosed with hemophilia or other significant bleeding disorders. Evidence of this diagnosis must be provided by your clinician or HTC. It is the applicant’s responsibility to notify the clinician or HTC that this verification is required.
• Any individual whose immediate family member (parent/sibling) is attached to the hemophilia/bleeding disorder community. Evidence of this must be provided by their clinician or HTC.
   

For more than 20 years, Pfizer has provided educational support to students living with hemophilia. Named in honor of a pioneer in the field of hemophilia research, the Soozie Courter Hemophilia Scholarship Program is designed to inspire students living with hemophilia to achieve their educational goals. 

Scholarships will be awarded to applicants with hemophilia A or hemophilia B who present the best combination of a creative and persuasive essay, excellent recommendations, and superior academic standing. 

College and Vocational School Scholarships

• Awarded to 12 individuals in the amount of $2,500.00
• Have been diagnosed with hemophilia A or hemophilia B
• Reside in the continental United States
• Meet one of the following criteria:
  • Be a high school senior in a school in the United States
  • Have completed high school or an equivalent (eg, general equivalency diploma [GED])
  • Be currently accepted to or enrolled in a junior college, college (undergraduate or graduate), or vocational school 

Graduate School Scholarship

• Awarded to 1 individual in the amount of $5,000.00
• Have been diagnosed with hemophilia A or hemophilia B
• Reside in the continental United States
• Be currently accepted to or enrolled in a junior college, college (undergraduate or graduate), or vocational school

Each year, the Kevin Child Scholarship is awarded to an exceptional student in memory of Kevin Child. As a child born with hemophilia in the late 1960s, Kevin had lived a life filled with challenges from the start. When he died of AIDS-related complications in 1989, he was just a few days short of his college graduation. In honor of Kevin's legacy, the Child family hopes this scholarship program will provide some assistance for students striving to acquire a higher education. [Kevin Child Scholarship applications are only being accepted by email. Please email your completed application to (jangarola@bleeding.org). If you have already mailed in your application, please contact Jonathan Angarola by email to confirm your materials have been received.]

Eligibility

• must be individuals diagnosed with either hemophilia A or B
• a high school senior with aspirations of attending an institute of higher education (college, university or vocational-technical school), or a college student already pursuing a post-secondary education

Novo Nordisk offers students with hemophilia and rare bleeding disorders the opportunity to apply for competitive scholarships for tuition to college and vocational schools. Eligible students can follow their dreams with one of five $4,000 4-year college scholarships or ten $2,500 community or vocational scholarships. 

Eligibility:

• Have commercial insurance
• Be a US resident
• Have one of the following hemophilia or rare bleeding disorders: hemophilia A, hemophilia B, hemophilia A or B with inhibitors, congenital factor VII deficiency, congenital factor XIII deficiency subunit-A, acquired hemophilia, and Glanzmann’s thrombasthenia with a refractoriness to platelets